References
- Mather R, Karenchak LM, Romanowski EQ, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002;133: 463–6
- Silver LH, Woodside AM, Montgomery DB. Clinical safety of moxifloxacin ophthalmic solution 0.5% (Vigamox) in pediatric and nonpediatric patients with bacterial conjunctivitis. Surv Ophthalmol 2005;50\(Suppl 1)S55–S63
- VIGAMOX [package insert]. Fort Worth (TX): Alcon Laboratories Inc.; 2003
- ZYMAR [package insert]. Irvine (CA): Allergan Inc.; 2003
- Chang SW, Chi RF, Wu CC, Su MJ. Benzalkonium chloride and gentamicin cause a leak in corneal epithelial cell membrane. Exp Eye Res 2000;71:3–10
- Tripathi BJ, Tripathi RC, Kolli SP. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic Res 1992;9:361–75
- Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001;18:205–15
- Burka JM, Bower KS, VanRoekel RC, et al. The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy. Am J Ophthalmol 2005;140:83–7
- Cutarelli PE, Lass, JH, Lazarus HM, et al. Topical fluoroquinolones: antimicrobial activity and in vitro corneal epithelial toxicity. Curr Eye Res 1991;10:557–63
- Kovoor TA, Kim AS, McCulley JP, et al. Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy. Eye Contact Lens 2004;30:90–4
- Jester JV, Maurer JK, Petroll WM, et al. Application of in vivo confocal microscopy to the understanding of surfactant-induced ocular irritation. Toxicol Pathol 1996;24:412–28
- Herrygers LA, Noecker RJ, Lane LC, Levine JM. Comparison of corneal surface effects of gatifloxacin and moxifloxacin using intensive and prolonged dosing protocols. Cornea 2005;24: 66–71
- Kowalski RP, Romanowski EG, Mah FS, et al. Intracameral Vigamox® (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol 2005;140: 497–504
- Kleinmann G, Larson S, Neuhann IM, et al. Intraocluar concentrations of gatifloxacin and moxifloxacin in the anterior chamber via diffusion through the cornea using collagen shields. Cornea 2006;25:209–13
- Price MO, Price Jr FW, Maclellan D. Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens. J Cataract Refract Surg 2005;31:2137–41
- Durrie DS, Trattler W. A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK. J Ocular Pharm Ther 2005;21:236–41